<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720070</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000597895</org_study_id>
    <secondary_id>WMS-PET-NECK</secondary_id>
    <secondary_id>ISRCTN13735240</secondary_id>
    <secondary_id>EU-20856</secondary_id>
    <secondary_id>MREC-07/Q1604/35</secondary_id>
    <secondary_id>UKCRN ID: 3799</secondary_id>
    <nct_id>NCT00720070</nct_id>
  </id_info>
  <brief_title>PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer</brief_title>
  <official_title>A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warwick Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures, such as PET/CT scan, produce pictures of areas inside the body&#xD;
      and may help doctors detect residual disease and plan the best treatment. Neck dissection is&#xD;
      surgery to remove lymph nodes and other tissues in the neck. It is not yet known whether a&#xD;
      neck dissection should always be performed in treating patients with head and neck cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying PET/CT scan-guided watchful waiting&#xD;
      compared with neck dissection of locally advanced lymph node metastases in treating patients&#xD;
      who are undergoing chemotherapy and radiation therapy for primary head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To compare the efficacy, in terms of overall survival, disease-specific survival,&#xD;
           recurrence, quality of life, and cost-effectiveness, of a PET/CT scan-guided watch and&#xD;
           wait policy with the current practice of planned neck dissection in the management of&#xD;
           advanced (N2 or N3) nodal metastases in patients with primary head and neck squamous&#xD;
           cell carcinoma undergoing chemoradiotherapy.&#xD;
&#xD;
        -  To assess the predictive value of PET/CT scanning in detecting persistent or residual&#xD;
           disease in the primary site.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to center,&#xD;
      chemotherapy schedule (concurrent platinum vs concurrent cetuximab vs neoadjuvant and&#xD;
      concurrent platinum vs neoadjuvant docetaxel, platinum, and fluorouracil with concurrent&#xD;
      platinum), T stage (T1-T2 vs T3-T4), and N stage (N2a-N2b vs N2c-N3). Patients are randomized&#xD;
      to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo&#xD;
           PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of&#xD;
           primary site undergo neck dissection within 4 weeks.&#xD;
&#xD;
        -  Arm II: Patients undergo neck dissection and then receive standard CRT. Patients undergo&#xD;
           PET/CT scan at 9-13 weeks after completion of CRT.&#xD;
&#xD;
      Patients are assessed periodically for quality-of-life. Tissue and blood samples collected&#xD;
      periodically are stored for future research.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 1 year and then&#xD;
      bimonthly for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 2 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Health economics using quality adjusted life years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence and local control in neck</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility cost</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of PET-CT scanning for assessing primary tumor</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography/computed tomography</intervention_name>
    <description>Patients undergo PET/CT scan</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Patients undergo neck dissection</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed head and neck squamous cell carcinoma (HNSCC), including any&#xD;
             of the following subtypes:&#xD;
&#xD;
               -  Oropharyngeal&#xD;
&#xD;
               -  Laryngeal&#xD;
&#xD;
               -  Oral&#xD;
&#xD;
               -  Hypopharyngeal&#xD;
&#xD;
          -  No primary nasopharyngeal carcinoma&#xD;
&#xD;
          -  Must have clinical and CT/MRI evidence of nodal metastases staged N2 (a, b, or c) or&#xD;
             N3&#xD;
&#xD;
               -  No occult nodal metastasis (i.e., large nodal metastasis but no proven primary&#xD;
                  site on clinical assessment)&#xD;
&#xD;
               -  No N1 nodal metastasis&#xD;
&#xD;
          -  Planning to receive curative radical concurrent chemoradiotherapy (approved by study)&#xD;
             for primary disease&#xD;
&#xD;
               -  Patients undergoing neoadjuvant chemotherapy followed by concurrent&#xD;
                  chemoradiotherapy are eligible&#xD;
&#xD;
          -  Able to undergo neck dissection surgery&#xD;
&#xD;
          -  No current resection for primary tumor planned (e.g., resection of tonsil or base of&#xD;
             tongue with flap reconstruction [diagnostic tonsillectomy allowed])&#xD;
&#xD;
          -  No distant metastases to chest, liver, bones, or other sites&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No other cancer diagnosis within the past 5 years except basal cell carcinoma or&#xD;
             cervical carcinoma in situ&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior treatment for HNSCC&#xD;
&#xD;
          -  No concurrent neoadjuvant chemoradiotherapy without concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent adjuvant chemotherapy&#xD;
&#xD;
          -  No concurrent chemoradiotherapy for palliative purposes&#xD;
&#xD;
          -  No concurrent radiotherapy alone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham Mehanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Warwick Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warwick Medical School Clinical Trials Unit</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV4 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisham Mehanna, MD</last_name>
      <phone>44-247-696-5606</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

